BlackRock Amends Coherus BioSciences Stake as of Dec 31, 2023
Ticker: CHRS · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1512762
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Coherus BioSciences stake, signaling a potential shift in institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership of Coherus BioSciences Inc. common stock as of December 31, 2023. This amendment, the third for BlackRock, shows their continued significant, though potentially adjusted, passive investment in the biotechnology company. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal their confidence (or lack thereof) in Coherus's future prospects, potentially influencing other investors.
Why It Matters
This filing shows BlackRock's updated passive ownership in Coherus BioSciences, which can influence market perception and investor sentiment for the stock.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate high-risk events for Coherus BioSciences.
Analyst Insight
An investor should note BlackRock's continued, albeit adjusted, passive stake in Coherus BioSciences, but should seek the full filing to understand the specific change in share count before making any investment decisions.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Coherus BioSciences, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 3)'.
Who is the filer of this SC 13G/A?
The filer of this SC 13G/A is BlackRock Inc., as stated under the 'FILED BY' section and on the cover page.
What is the subject company of this filing?
The subject company is Coherus BioSciences, Inc., as identified under 'SUBJECT COMPANY' and 'Name of Issuer' on the cover page.
What is the CUSIP number for the securities reported?
The CUSIP number for the Common Stock of Coherus BioSciences Inc. is 19249H103, as listed on the cover page.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Coherus BioSciences, Inc. (CHRS).